BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37744220)

  • 1. Performance of multigene testing in cytologically indeterminate thyroid nodules and molecular risk stratification.
    Zhou Y; Wu X; Zhang Y; Li Z; Ge X; Chen H; Mao Y; Ding W
    PeerJ; 2023; 11():e16054. PubMed ID: 37744220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A five-gene panel refines differential diagnosis of thyroid nodules.
    Lu SY; Chen YC; Zhu CF; Chen J; Zhou QY; Zhang MM; Zhang QY; Lu M; Yang L; Wu J; Zhao SX; Song HD; Ye XP
    J Clin Lab Anal; 2021 Sep; 35(9):e23920. PubMed ID: 34318534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China.
    Song Y; Xu G; Ma T; Zhu Y; Yu H; Yu W; Wei W; Wang T; Zhang B
    Cancer Med; 2020 Nov; 9(22):8397-8405. PubMed ID: 32976686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
    An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
    Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.
    Skaugen JM; Taneja C; Liu JB; Wald AI; Nikitski AV; Chiosea SI; Seethala RR; Ohori NP; Karslioglu-French E; Carty SE; Nikiforova MN; Yip L; Nikiforov YE
    Thyroid; 2022 Dec; 32(12):1500-1508. PubMed ID: 35864811
    [No Abstract]   [Full Text] [Related]  

  • 9. A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology-A Pilot Cohort Study.
    Gomes-Lima CJ; Auh S; Thakur S; Zemskova M; Cochran C; Merkel R; Filie AC; Raffeld M; Patel SB; Xi L; Wartofsky L; Burman KD; Klubo-Gwiezdzinska J
    Front Endocrinol (Lausanne); 2020; 11():53. PubMed ID: 32132976
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
    Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
    Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.
    Liu S; Gao A; Zhang B; Zhang Z; Zhao Y; Chen P; Ji M; Hou P; Shi B
    Exp Mol Pathol; 2014 Oct; 97(2):292-7. PubMed ID: 25111330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
    Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules.
    Fu G; Chazen RS; Monteiro E; Vescan A; Freeman JL; Witterick IJ; MacMillan C
    JAMA Netw Open; 2023 Jul; 6(7):e2323500. PubMed ID: 37505499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 17. BRAF V600E as an accurate marker to complement fine needle aspiration (FNA) cytology in the guidance of thyroid surgery in the Chinese population: evidence from over 1000 consecutive FNAs with follow-up.
    Zhao Q; Wang Y; Ye Q; Wang P; Rao J
    Jpn J Clin Oncol; 2021 Apr; 51(4):590-594. PubMed ID: 33237284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of multi-gene testing in benign or malign diagnosis of thyroid nodules with indeterminate cytology].
    Song YT; Xu GH; Zhu YL; Ma TH; Yu H; Wang TX; Yu WB; Wei W; Zhang B
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Oct; 54(10):764-768. PubMed ID: 31606990
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
    Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
    Dell'Aquila M; Fiorentino V; Martini M; Capodimonti S; Cenci T; Lombardi CP; Raffaelli M; Pontecorvi A; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2021 Oct; 129(10):819-829. PubMed ID: 34076961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.